Glenmark Of India Plans U.S. Acquisition To Market Specialty Drugs
This article was originally published in PharmAsia News
India's Glenmark Pharmaceuticals plans to acquire a U.S. company in a move to enter the U.S. market for its specialty drugs business. Currently, Glenmark specialty products are marketed in all markets except the United States and Japan. Glenmark CEO Glenn Saldanha would not comment on the size or timing of an acquisition, but confirmed the company does want to market its specialty products in regulated markets, particularly the United States. That product line is expected to be worth $35 million to the firm in the next fiscal period. (Click here for more
You may also be interested in...
PharmAsia News India Pharma Roundup: Glenmark, FMRAI, Synchron/Parexel, Suven Life Sciences, Merck/Ranbaxy/Teva/Credit Suisse
NEW DELHI - Mumbai-based Glenmark Pharmaceuticals has split its corporate structure into speciality and generic units to better manage the "diverse businesses that had both attained a critical mass.
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.